Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30992968 | 1.00 | CYP3A4 (0.68) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5207755 | 0.89 | ALDH1A1 (0.59) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL26372738 | 0.86 | CYP3A4 (0.73) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL6630039 | 0.85 | CYP3A4 (0.62) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL7148530 | 0.85 | CYP3A4 (0.72) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL29642680 | 0.84 | CYP3A4 (0.75) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3944098 | 0.84 | CYP3A4 (0.75) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL138875 | 0.84 | CYP3A4 (0.75) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL29364835 | 0.83 | CYP3A4 (0.62) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL7406 | 0.83 | CYP3A4 (0.62) | CYP3A4ALDH1A1CYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250033082-A1 | METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS | ADAMA MAKHTESHIM LTD. (IL) | 2025-01-30 | — | — | US | claimed |
| EP-4423178-A1 | METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS | ADAMA MAKHTESHIM LTD. (IL) | 2024-09-04 | — | — | EP | claimed |
| CN-118201991-A | Methods and compositions for reducing solvent release from agrochemical formulations and reducing agrochemical formulation odor | 安道麦马克西姆有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-11906456-B2 | Sensor element, sensor device, sensor system and detection method | KABUSHIKI KAISHA TOSHIBA (JP) | 2024-02-20 | — | — | US | claimed |
| WO-2023073536-A1 | METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS | ADAMA MAKHTESHIM LTD. (IL) | 2023-05-04 | — | — | WO | claimed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2021030571-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-18 | — | — | WO | claimed |
| JP-8081468-A | — | — | None | — | — | JP | disclosed |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | APOAPSIS HOLDINGS, LLC (US) | 2026-04-14 | — | — | US | disclosed |
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4662205-A1 | DERIVATIVES, IMMUNOGENS, AND ANTIBODIES AND USE OF THE SAME IN DETECTION OF ECSTASY-CLASS COMPOUNDS | Siemens Healthcare Diagnostics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-0004929-B1 | INSECTICIDAL AND ACARICIDAL COMPOSITIONS COMPRISING ISOCHROMAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BAYER AG (DE) | 1981-04-08 | — | — | EP | disclosed |
| US-4247560-A | 6,7-Methylenedioxy-isochromane arthropodicide synergizing agents | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-27 | — | — | US | disclosed |
| EP-0021840-A1 | Heterocyclic compounds, processes for their preparation and compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-01-07 | — | — | EP | disclosed |
| EP-0004929-A2 | Insecticidal and acaricidal compositions comprising isochroman derivatives, process for their preparation and application | BAYER AG (DE) | 1979-10-31 | — | — | EP | disclosed |
| US-4058607-A | DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES | AIRWICK INDUSTRIES, INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-3962415-A | Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer | AIRWICK INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | SLC6A3, SLC6A2, HTR2C | CYP3A4 576/4885ALDH1A1 1951/4885CYP1A2 148/4885 |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | OPRM1, DRD3, SLC6A3 | CYP3A4 106/4885ALDH1A1 614/4885CYP1A2 33/4885 |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | SLC18A2, SLC6A3, GAP43 | CYP3A4 480/4885ALDH1A1 1753/4885CYP1A2 345/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | CYP3A4 194/4885ALDH1A1 1469/4885CYP1A2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.